- Home
- CCJ vs BGNE Comparison
CCJ vs BGNE Comparison
Compare CCJ & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCJ
- BGNE
- Stock Information
- Founded
- CCJ 1987
- BGNE 2010
- Country
- CCJ Canada
- BGNE Cayman Islands
- Employees
- CCJ N/A
- BGNE N/A
- Industry
- CCJ Other Metals and Minerals
- BGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CCJ Basic Materials
- BGNE Health Care
- Exchange
- CCJ Nasdaq
- BGNE Nasdaq
- Market Cap
- CCJ 23.6B
- BGNE 19.2B
- IPO Year
- CCJ N/A
- BGNE 2016
- Fundamental
- Price
- CCJ $51.94
- BGNE $175.87
- Analyst Decision
- CCJ Strong Buy
- BGNE Buy
- Analyst Count
- CCJ 4
- BGNE 8
- Target Price
- CCJ $66.56
- BGNE $253.69
- AVG Volume (30 Days)
- CCJ 3.8M
- BGNE 476.1K
- Earning Date
- CCJ 02-06-2025
- BGNE 11-12-2024
- Dividend Yield
- CCJ 0.22%
- BGNE N/A
- EPS Growth
- CCJ N/A
- BGNE N/A
- EPS
- CCJ 0.19
- BGNE N/A
- Revenue
- CCJ $2,069,888,595.00
- BGNE $3,351,304,621.00
- Revenue This Year
- CCJ $17.28
- BGNE $969.39
- Revenue Next Year
- CCJ $8.80
- BGNE $24.79
- P/E Ratio
- CCJ $269.61
- BGNE N/A
- Revenue Growth
- CCJ 23.31
- BGNE 50.22
- 52 Week Low
- CCJ $35.43
- BGNE $126.97
- 52 Week High
- CCJ $62.55
- BGNE $248.16
- Technical
- Relative Strength Index (RSI)
- CCJ 36.85
- BGNE 34.52
- Support Level
- CCJ $55.78
- BGNE $174.50
- Resistance Level
- CCJ $57.90
- BGNE $180.00
- Average True Range (ATR)
- CCJ 2.22
- BGNE 6.73
- MACD
- CCJ -1.00
- BGNE -2.17
- Stochastic Oscillator
- CCJ 2.26
- BGNE 3.24
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
About BGNE BeiGene Ltd.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.